Skip to main content
PharmaGraphX
PharmaGraphX
Log inGet Started

Important Disclaimer

PharmaGraphX is a research and educational tool only. It is NOT intended for clinical decision-making, patient care, or medical advice. All drug information, calculations, interactions, and recommendations are for educational and research purposes only. Always consult qualified healthcare professionals, official drug labeling (FDA, TGA, EMA), and institutional guidelines before making any clinical decisions. The developers assume no liability for any decisions made based on information provided by this platform.

© 2026 PharmaGraphX. All rights reserved.

|

For research and educational purposes only. Not medical advice.

Help
  • Navigate between workspaces using the left sidebar.
  • Use the main chat to ask any pharmacology question.
  • Press G then H to quickly navigate home.
Navigation
HomeG H
PK/PD StudioG P
Interaction HubG A
Digital TwinG T
Molecular LabG M

Press Esc to close

  1. Home
  2. /Database
  3. /Rituximab

Rituximab

Rituxan, Truxima, Ruxience, Rituxan Hycela, Riabni

Biologic • Anti-CD20 monoclonal antibody

Premium
HepatotoxicNephrotoxic

Half-life

22 days (after first dose); 76 days (after fourth dose)

Protein Binding

Metabolized By

Proteolytic degradation

External

Drugs.com

Mechanism of Action

Chimeric antibody targeting CD20 on B lymphocytes, causing B-cell depletion

Indications(5)

Granulomatosis With PolyangiitisAnti-neutrophil Cytoplasmic Antibody-associated VasculitisAnn Arbor Stage II Grade 1 Contiguous Follicular LymphomaAnn Arbor Stage II Grade 1 Non-Contiguous Follicular LymphomaAnn Arbor Stage II Grade 2 Contiguous Follicular Lymphoma

Classification

Drug Class

Biologic

Subclass

Anti-CD20 monoclonal antibody

Brand Names

RituxanTruximaRuxienceRituxan HycelaRiabni

Key Properties

Half-life

22 days (after first dose); 76 days (after fourth dose)

Time for plasma concentration to decrease by 50%

Protein Binding

—

Fraction bound to plasma proteins

Therapeutic Index

Wide

Margin between therapeutic and toxic doses

Not a substitute for clinical judgement
Rituximab Drug Profile | PharmaGraphX